For almost a decade, President Biden has championed a bold “cancer moonshot” — an initiative he first launched in 2016, revived early in his administration, and reiterated during this year’s State of the Union. It is a laudable goal, especially for an aging nation where cancer and chronic disease are on the rise. There’s just one problem: Recent federal and state policies are poised to derail the incredible progress made in oncology since 2016. A rash of policies now threatens to limit access and slow progress towards new breakthroughs.

The Global Coalition on Aging (GCOA) last week issued a report calling on G7 countries to commit to funding pull incentives and making other investments in antibiotic innovation.

Common infections will kill millions if drug resistance through misuse of antibiotics is not curbed, says England’s ex-chief medical officer

It kills millions every year, with a potential impact in the near future that could dwarf that of the Covid-19 pandemic but AMR, or antimicrobial resistance, remains a little-known problem outside specialist circles.

The AMR Action Fund announced that one of its portfolio companies, UTILITY Therapeutics, Ltd., received approval from the U.S. Food and Drug Administration (FDA) for the antibiotic PIVYA™ (pivmecillinam) for the treatment of uncomplicated UTIs (uUTI).